FINWIRES · TerminalLIVE
FINWIRES

Thermo Fisher, Danaher Could Log Mid-Single-Digit Organic Revenue Growth in 2027, UBS Says

By
Thermo Fisher, Danaher Could Log Mid-Single-Digit Organic Revenue Growth in 2027, UBS Says

Thermo Fisher Scientific (TMO) and Danaher (DHR) are likely to return to mid-single-digit organic revenue growth in 2027, UBS Securities said in separate notes e-mailed Wednesday.

Thermo Fisher is expected to "durably return" to organic revenue gain of at least 5% to 6% next year, expand its operating margin by at least 50 to 70 basis points and generate double-digit per-share earnings growth, UBS analyst Douglas Schenkel wrote in a note to clients.

The medical device manufacturer's core end markets have "largely rebounded with structural tailwinds in place," Schenkel said. UBS sees "some green shoots" in the company's tail exposures that have been slower to improve.

Factors such as improved funding, investment reshoring, and continued robust demand for bioprocessing tools and services should help Thermo Fisher generate mid-single- to high-single-digit revenue growth, the brokerage said. The company is expected to benefit from stabilization in China, along with other factors, according to the note.

"We believe 5.5% to 7% core revenue growth is achievable without assuming a material improvement in the (academic and government) end market," Schenkel said.

In July, Thermo Fisher posted stronger-than-expected second-quarter results.

Separately, UBS said it sees Danaher returning to low-single-digit organic growth in 2026 and mid-single-digit next year. Capital deployment is likely to bridge medical equipment maker back toward its high-single-digit algorithm, an inflection that the brokerage said could rebuild the company's historical valuation premium.

Investor patience with Danaher is "quite low" amid its latest bioprocessing slip in the second quarter, Schenkel wrote in a separate note. During an earnings call in July, the company flagged a "conservative" outlook for the bioprocessing segment, due to "some of the customer-driven timing dynamics" seen in its second quarter, according to a FactSet transcript.

Danaher's bioprocessing division is continuing to recover, while the life sciences business is reaccelerating as end markets normalize, UBS said. The brokerage sees diagnostics growth in a position to re-rate under incoming Chief Executive Julie Montgomery.

UBS has buy ratings on the respective stocks of Thermo Fisher and Danaher. The brokerage's rating history shows Thermo Fisher was most recently rated neutral.

Price: $605.70, Change: $+2.68, Percent Change: +0.44%

Related Articles

China's Consumer, Producer Inflation Pick Up on Upstream Cost Pressures
US Markets

China's Consumer, Producer Inflation Pick Up on Upstream Cost Pressures

China's consumer and producer prices strengthened in August, signaling firmer price pressures as higher commodity and input costs fed through the industrial sector.The consumer price index rose 0.8% year over year in August, according to data from the National Bureau of Statistics on Wednesday. The reading matched the 0.8% consensus forecast tracked by Investing.com and picked up from 0.5% in July.The CPI rose 0.4% month over month, rebounding after three consecutive months of declines and suggesting a firmer near-term price trend.The recovery, however, remained uneven. Food prices fell 1.4% year over year, while non-food prices rose 1.2%. Consumer goods prices increased 0.8%, matching the rise in services prices.Core inflation, which excludes food and energy, rose 1% year over year, pointing to somewhat firmer underlying price pressures than the headline CPI suggests.Producer prices delivered a stronger signal. The PPI rose 3.8% year over year in August, recovering from a three-month low of 3.5% in July and exceeding the 3.6% consensus forecast tracked by Investing.com.On a month-over-month basis, the PPI rose 0.4%, reversing two consecutive months of declines.The rebound was led by production inputs, with prices of means of production rising 5% year over year. Mining prices jumped 17.8%, while raw-material prices rose 6.7%.Higher commodity and industrial input costs remained a key source of pressure. Prices of non-ferrous metal materials and wires surged 19.8% year over year, while fuel and power prices rose 9.8% and chemical raw-material prices increased 9.5%.Taken together, the data suggest China's price environment is becoming firmer, although the recovery remains uneven.For the first eight months, consumer prices averaged 0.9% higher than a year earlier, compared with a 2% increase in producer prices.

Shanghai Composite^SZSE
Chip, Drug Makers to Drive Non-Residential Construction Rebound, UBS Says
US Markets

Chip, Drug Makers to Drive Non-Residential Construction Rebound, UBS Says

US non-residential construction is approaching a reacceleration, driven by semiconductor and pharmaceutical investments, UBS Securities said in a note emailed Tuesday.The brokerage expects manufacturing-related construction to rebound to more than $200 billion by the end of next year following a 25% drop to $186 billion in the last 12 months.Electric vehicle and battery plants, as well as semiconductor investments, drove the previous buildout cycle from 2021 to 2024, UBS analysts, including Steven Fisher, said."Our analysis and project tracking continues to suggest the drivers this cycle will be another round of semiconductor factories and pharmaceutical projects, in addition to some general industrial and defense related investments," Fisher wrote.UBS upgraded its 2027 growth outlook for non-residential construction to 6.7% from 6%, while lowering the 2026 view to show a 0.9% drop, all in nominal terms.The semiconductor industry has announced nearly $300 billion in year-to-date investments, according to the note. The CHIPS and Science Act, which became law in 2022, initially boosted capacity expansion, but companies have reassessed plans over the last one to two years."For some time, semiconductor manufacturers have remained relatively disciplined in their capacity expansion plans, preferring to add capacity in response to demand rather than build ahead of it," Fisher said. "That demand now appears firmly in place."Pharmaceutical companies have announced about $400 billion in new investments over the last two years, including a commitment of at least $20 billion from Eli Lilly (LLY), amid surging demand for weight loss drugs, the UBS note showed.Defense spending is also on the rise due to the evolving geopolitical situation."In addition to structural drivers discussed above, we think that cyclical drivers will add to growth," Fisher said.The Institute for Supply Management's purchasing managers' index has been expanding for eight months in a row following three years of sluggish performance, according to the brokerage. Separately, S&P Global (SPGI) said last week that manufacturing growth held steady sequentially in August.UBS said equipment rental firm United Rentals (URI) is the main beneficiary of the manufacturing capacity expansion.The brokerage is also positive on United Rentals' peer Equipmentshare.com (EQPT) and construction machinery names Oshkosh (OSK), Caterpillar (CAT), Deere (DE) and CNH Industrial (CNH).Materials providers like Martin Marietta Materials (MLM) and CRH (CRH) and some companies in the engineering and construction sector will also benefit from a pickup in factory activity, according to the note.

$CAT$CNH$CRH$DE$EQPT$LLY$MLM$OSK$SPGI$URI
Update: Equities Dip, Oil Jumps as Middle East Tensions Escalate
US Markets

Update: Equities Dip, Oil Jumps as Middle East Tensions Escalate

(Updates with market moves at the end of the day, and other changes, if any.)US stocks fell for a second consecutive session on Tuesday as heightened tensions in the Middle East drove oil prices higher.The Dow Jones Industrial Average closed 1.2% lower at 52,786.07, while the S&P 500 shed 0.6% to 7,673.52. The Nasdaq Composite dipped 0.3% to 26,421.41. US markets were closed Monday for the Labor Day holiday.Most sectors ended in the red, led by healthcare, while energy paced the gainers.West Texas Intermediate crude oil rose 2.4% to $93.71 a barrel in Tuesday late-afternoon trade, having hit a high of $94.73 earlier in the day. Brent crude climbed 1.9% to $98.79, after advancing earlier to reach an intraday peak of $99.46.Yemen's Iran-allied Houthi group struck civilian and economic sites in Saudi Arabia, injuring 73 people, the kingdom's Ministry of Foreign Affairs said Tuesday. The Houthi group targeted Saudi Aramco's facilities across Abha, Najran, and Jazan, Bloomberg News reported, citing the group's military spokesperson.US Central Command said Saturday that its forces targeted three Iranian oil tankers on Saturday in response to Tehran firing ballistic missile at two American Navy warships.Treasury yields were higher, with the two-year rate up 1.7 basis points at 4.4% and the 10-year rate rising 0.8 basis point to 4.79%.US consumers had mixed views on the inflation trajectory in August, seeing prices hold steady in the short- and long-term but expecting a drop over the next three years, a survey by the Federal Reserve Bank of New York showed Tuesday.The August consumer and producer price data for August, due out later this week, could serve as crucial data points for the Federal Open Market Committee, which begins its two-day policy meeting Tuesday next week.Markets are pricing in a 59% probability that the FOMC will raise the benchmark lending rate by 25 basis points on Sept. 16, with the remaining odds pointing to another Fed pause, according to the CME FedWatch tool.In company news, Boston Scientific (BSX) shares fell 5.9% after the medical device maker said it may not be able to meet its own guidance, citing a "material impact" from a recent cybersecurity incident.ABM Industries (ABM) tightened its full-year earnings outlook as the facility services provider's bottom line for the fiscal third quarter topped market estimates. The company's shares jumped 7.6%.S&P 500 companies' second-quarter earnings growth continues to outpace early forecasts as the reporting season draws to a close, Oppenheimer Asset Management said Tuesday.Cloud computing giant Oracle (ORCL) and photoshop maker Adobe (ADBE) are scheduled to report results later in the week.Spot gold dropped 1.1% to $4,357.46 per troy ounce, while silver edged down 0.4% to $66.50 per ounce.

Dow JonesNasdaq CompositeS&P 500$ABM$ADBE$BSX$ORCL